Stephen Farrelly
Stephen Farrelly is the global head of pharma and healthcare at ING, where he analyzes market trends and their implications for consumers. He has highlighted that the imposition of tariffs on generic drugs could significantly increase costs for consumers, particularly those without insurance, who would be hit hardest by rising drug prices resulting from these tariffs.
Not in the pool (under ¢1).
Recent news mentions
Stephen Farrelly is the ING global pharma and healthcare lead who expressed concerns about the potential drag on the vaccine sector.
Drugmakers take hit from the US’ anti-vax changes
Taiwan· 2026-01-25
Stephen Farrelly, ING’s global health care sector lead, explained the complexities of drug pricing in the US.
Drugmakers are pouring billions of dollars into new US manufacturing. It still won’t achieve all of Trump’s tariff goals
United States· 2025-08-02
Stephen Farrelly, global lead for pharma and healthcare at ING, says tariff threats have been a catalyst for pharmaceutical firms.
Trump's investment claims - are tariffs boosting the US economy?
United Kingdom· 2025-06-16
Stephen Farrelly, global head of pharma and healthcare at ING, said the people who would be 'hardest hit' were those without insurance.
US tariffs on pharmaceuticals risk shortages of lower-cost generic drugs – The Irish Times
Ireland· 2025-04-21
